Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Xaira Therapeutics Inc.
Headquarters: San Francisco, CA, United States of America
Website: https://xaira.com/
Year Founded: 2023
Status: Private
See Emerging Company Profile .
BioCentury | Apr 4, 2025
Management Tracks
Ex-Dyne team members reconvene at Crescent
Plus: New staff at Neurocrine, Xaira and Dark Blue; Oz confirmed at CMS
BioCentury | Feb 6, 2025
Product Development
AI-based predictive biology coming soon, Foresite’s Bajaj says
CEO of Foresite Labs betting on integrating AI/MI with medical product R&D — The BioCentury Show
BioCentury | Jan 14, 2025
Finance
How VCs at the AI-bio interface set up their portfolios for success
Some firms are playing an active role in overcoming data starvation and bolstering the infrastructure ecosystem
BioCentury | Jan 10, 2025
Finance
Life science VCs driving AI innovation: the view from the interface in 2025
How VC firms focused on AI-driven drug development think about the resources and strategies needed to turn promise into reality
BioCentury | Dec 30, 2024
Product Development
The uncertainty principle: Hello, 2025
BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025
BioCentury | Dec 12, 2024
Management Tracks
Two more C-suite hires at Xaira
Plus: Accent’s Copeland to retire and updates from ProQR, Kashiv and Aculeus
BioCentury | Oct 18, 2024
Management Tracks
Co-founders Mulvaney, Brennan return to BenevolentAI as CEO Moeller departs
Plus: Sage downsizes and updates from Xaira, DNA Script, Renovaro, Achieve, Adverum and more
BioCentury | Oct 11, 2024
Product Development
Discovery through perturbation: taking causality into your own hands
A company’s experimental setup and scale shape the type of AI it uses and questions it can ask
BioCentury | Oct 10, 2024
Discovery & Translation
Baker and DeepMind Nobel: Two sides of a computational protein coin
Protein design updates its engine: The field’s shift from physical models to deep learning
BioCentury | Oct 7, 2024
Discovery & Translation
Causal biology in the age of big data
Where do you start? Patient data might sound more obvious, but human cell-based models have advantages
Items per page:
1 - 10 of 16